Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension

被引:2
|
作者
Zuo, Yifan [1 ]
Li, Boyang [1 ]
Gao, Minglang [1 ]
Xiong, Rui [1 ]
He, Ruyuan [1 ]
Li, Ning [1 ]
Geng, Qing [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Thorac Surg, Wuhan 430060, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
Pulmonary hypertension; Macrophage; Hypoxia; Monocrotaline; Animal models; ARTERIAL-HYPERTENSION; ADVENTITIAL FIBROBLASTS; ALTERNATIVE ACTIVATION; INFLAMMATORY PHENOTYPE; ALVEOLAR MACROPHAGES; ENDOTHELIAL-CELLS; PROGENITOR CELLS; PATHOGENESIS; CONTRIBUTES; RECRUITMENT;
D O I
10.1186/s12931-024-02772-8
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Inflammation and immune processes underlie pulmonary hypertension progression. Two main different activated phenotypes of macrophages, classically activated M1 macrophages and alternatively activated M2 macrophages, are both involved in inflammatory processes related to pulmonary hypertension. Recent advances suggest that macrophages coordinate interactions among different proinflammatory and anti-inflammatory mediators, and other cellular components such as smooth muscle cells and fibroblasts. In this review, we summarize the current literature on the role of macrophages in the pathogenesis of pulmonary hypertension, including the origin of pulmonary macrophages and their response to triggers of pulmonary hypertension. We then discuss the interactions among macrophages, cytokines, and vascular adventitial fibroblasts in pulmonary hypertension, as well as the potential therapeutic benefits of macrophages in this disease. Identifying the critical role of macrophages in pulmonary hypertension will contribute to a comprehensive understanding of this pathophysiological abnormality, and may provide new perspectives for pulmonary hypertension management.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] New insights into chronic thromboembolic pulmonary hypertension
    Brito, Joao
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2023, 42 (12) : 959 - 960
  • [22] New insights in the pathogenesis of pulmonary arterial hypertension
    Bordenave, J.
    Tu, L.
    Savale, L.
    Huertas, A.
    Humbert, M.
    Guignabert, C.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (04) : 433 - 437
  • [23] Diagnosis and Management of Pulmonary Hypertension: New Insights
    Ntiloudi, Despoina
    Kasinos, Nearchos
    Kalesi, Alkistis
    Vagenakis, Georgios
    Theodosis-Georgilas, Anastasios
    Rammos, Spyridon
    DIAGNOSTICS, 2024, 14 (18)
  • [24] Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Mielniczuk, Lisa M.
    Swiston, John R.
    Mehta, Sanjay
    CANADIAN JOURNAL OF CARDIOLOGY, 2014, 30 (10) : 1233 - 1240
  • [25] Pulmonary arterial hypertension: New therapeutic modalities
    Pitsiou, G. G.
    Argiropoulou-Pataka, P.
    PNEUMON, 2005, 18 (02) : 144 - 155
  • [26] New Therapeutic Target for Pulmonary Arterial Hypertension
    Yoon, Kyung Lim
    KOREAN CIRCULATION JOURNAL, 2018, 48 (12) : 1145 - 1147
  • [27] A New Therapeutic Alternative for the Treatment of Pulmonary Hypertension?
    Gelpi, Ricardo J.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 117 (06) : 1113 - 1114
  • [28] Pulmonary Artery Denervation A New Therapeutic for Pulmonary Arterial Hypertension?
    Leopold, Jane A.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2022, 15 (23) : 2424 - 2426
  • [29] New Insights into Phosphodiesterase 1C as a Novel Target for Pulmonary Arterial Hypertension
    Al Bakour, Zaher
    Hislop, James
    Breitenbucher, James
    Murray, Fiona
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (02) : 424 - 425
  • [30] PHOSPHODIESTERASE 2 IS A NOVEL THERAPEUTIC TARGET IN PULMONARY HYPERTENSION
    Hobbs, A.
    Bubb, K.
    Trinder, S.
    Baliga, R.
    MacAllister, R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 40 - 41